Updated Interim Results Show [212Pb]VMT-α-NET Promising in Neuroendocrine Tumors

The [212Pb]VMT-α-NET study, presented at the 2025 ASCO Annual Meeting, reported updated interim results from a Phase 1/2a study in neuroendocrine tumors. Four of seven patients in Cohort 2 experienced objective responses, and seven of nine patients in Cohorts 1 and 2 remained free from disease progression after more than one year of follow-up. The treatment had a favorable safety profile with no dose-limiting toxicities or discontinuations due to adverse events. The FDA was aligned to open Cohort 3 of the study.

Perspective Therapeutics, Inc. (NYSE: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, recently reported its Q2 2025 financial results and provided updates on its clinical pipeline. The company's lead candidate, [212Pb]VMT-α-NET, showed promising interim results in neuroendocrine tumors, with four out of seven patients in Cohort 2 experiencing objective responses and seven of nine patients remaining progression-free after one year. The FDA approved the advancement to Cohort 3 (6.0 mCi) in June 2025.

The company reported $192M in cash as of June 30, 2025, expected to fund operations into late 2026. Q2 2025 financial results showed a net loss of $21.5M ($0.29 per share), compared to $11.7M in Q2 2024. R&D expenses increased by 79% to $16.6M, while G&A expenses rose by 40% to $7.7M. Clinical progress continues across three programs: VMT-α-NET, VMT01 for melanoma, and PSV359 for FAP-α expressing tumors.

Updated trial results for VMT-α-NET will be presented at the ESMO Congress 2025 in October. The company also announced that it plans to submit further updates to scientific forums on patients who have received treatments with its potential new medicines through mid-2026 and beyond.

[1] https://www.stocktitan.net/news/CATX/perspective-therapeutics-provides-recent-business-highlights-and-68iqw6zldxlw.html